ZEISS earns CE mark for CIRRUS PathFinder with fully integrated AI decision support for OCT diagnostics

ZEISS earns CE mark for CIRRUS PathFinder with fully integrated AI decision support for OCT diagnostics

(IN BRIEF) ZEISS Medical Technology has received CE mark approval for CIRRUS PathFinder, an integrated AI decision support tool for optical coherence tomography (OCT). The software, available as part of a new CIRRUS update, leverages deep learning algorithms to automatically flag abnormal macular B-scans and enhance OCTA image quality with multi-layer segmentation. CIRRUS PathFinder eliminates the need for external platforms, offering real-time assessment of hundreds of scans to streamline workflows and improve patient care. Alongside AI capabilities, the release features stronger cybersecurity, expanded connectivity, and a Reference Database three times larger than before. Compatible with CIRRUS 500, 5000, and 6000 devices, the new system underscores ZEISS’ commitment to advancing digitally connected ophthalmic care.

(PRESS RELEASE) JENA, 22-Aug-2025 — /EuropaWire/ — ZEISS Medical Technology has received CE mark approval for its new CIRRUS® PathFinder™ solution, an AI-enabled clinical support tool designed to improve the efficiency and confidence of ophthalmic diagnostics. Available as part of the latest CIRRUS software release, the system introduces deep learning algorithms directly into the OCT workflow, automatically highlighting abnormal macular OCT B-scans and providing AI-enhanced OCTA imaging quality with advanced multi-layer segmentation.

The CE approval paves the way for broader clinical adoption of AI-supported ophthalmic care across Europe. CIRRUS PathFinder is designed to help ophthalmologists streamline daily practice, accelerate interpretation, and deliver better patient outcomes without the need for third-party software.

“At ZEISS, our priority is to empower clinicians with digital solutions that make workflows more efficient, reduce costs, and improve the patient experience,” said Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. “By embedding AI decision support directly into CIRRUS PathFinder, we’re helping practitioners make faster, more confident, and actionable decisions.”

Euan S. Thomson, Ph.D., Head of the Digital Business Unit for ZEISS Medical Technology, added: “The future of ophthalmology is being shaped by data-driven, connected workflows. Our strategy to integrate AI across platforms positions ZEISS at the forefront of innovation, enabling clinicians with powerful digital tools such as CIRRUS PathFinder.”

The new software release extends the CIRRUS platform’s diagnostic capabilities by:

• Delivering AI-driven clinical support – Fully integrated decision support enables real-time analysis of hundreds of OCT scans, flagging areas that may need further review and allowing clinicians to concentrate on patient care rather than manual data processing.
• Enhancing OCTA imaging – AI-powered visualization improves structural scans, with expanded layer segmentation and sharper vascular imaging for more reliable interpretation.
• Ensuring security and connectivity – Cybersecurity upgrades strengthen compliance while supporting seamless integration of legacy OCT data with current diagnostic modalities.

“PathFinder AI Decision Support is a significant advancement in ophthalmic care, enabling clinicians to identify scans requiring closer attention and raising diagnostic precision to new levels,” said Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology.

CIRRUS PathFinder is available through a software license and is compatible with ZEISS CIRRUS 500, 5000, and 6000 devices. The expanded Reference Database included in the release has tripled in size compared to the previous version, and new AI-driven tools are initially available in select markets.

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

Media Contacts:

Sebastian Frericks
tel:+49 3641 220 116
investors.med@zeiss.com

Frank Smith
tel:+49 3641 220 331
press.med@zeiss.com

Source: ZEISS